LifeSci Capital analyst Charles Zhu maintained a Buy rating on Kura Oncology yesterday and set a price target of $24.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Charles Zhu has given his Buy rating due to a combination of factors including Kura Oncology’s promising clinical developments and financial stability. The company has reiterated its guidance for upcoming clinical data readouts, which include significant milestones such as the PDUFA date for ziftomenib in relapsed/refractory NPM1m AML and the initiation of Phase 3 trials for frontline NPM1m and KMT2Ar AML. Management expressed confidence in ziftomenib’s competitive profile, especially in the context of a strong competitor launch, which suggests potential for multiple treatment options in the market.
Additionally, Kura Oncology’s advancements in their farnesyltransferase inhibitor programs, with promising first-in-human readouts expected at ESMO, further support the Buy rating. The company’s financial health is robust, with $630.7 million in cash and marketable securities, providing an operating runway into 2027. This financial stability, combined with strategic clinical progress, underpins the positive outlook for Kura’s stock.